bioMerieux (BMXMF) Expected to Announce Earnings on Tuesday

bioMerieux (OTCMKTS:BMXMF) is anticipated to issue its resultson Tuesday, July 28th. Analysts expect the company to announce earnings of $2.32 per share and revenue of $2.2103 billion for the quarter.

bioMerieux Stock Performance

Shares of BMXMF opened at $78.99 on Friday. The company has a 50 day moving average price of $81.38 and a 200-day moving average price of $99.76. bioMerieux has a fifty-two week low of $77.00 and a fifty-two week high of $152.00. The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08.

Analysts Set New Price Targets

A number of equities analysts recently commented on BMXMF shares. Morgan Stanley downgraded shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research note on Tuesday, June 23rd. UBS Group cut bioMerieux from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Zacks Research raised bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. Finally, Piper Sandler started coverage on bioMerieux in a research note on Thursday, June 11th. They set a “neutral” rating for the company. Five research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce”.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.